Références et sites Internet

Sites proposés pour ce cancer

1 Statistiques Canadiennes sur le cancer 2016 www.cancer.ca

2 Ellison JH, Wu, XC, McLaughlin, C et coll. (éds.). Cancer in North America, 1999-2003. Volume one: Incidence; volume two: Mortality. mai 2006 ; Springfield, IL: North American Association of Central Cancer Registries Inc.

3 Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (éds.). 2002 ; Cancer incidence in five continents, volume VIII, Lyon : Publication scientifique du CIRC no 155, Centre international de recherche sur le cancer.

4 Statistiques Canadiennes sur le cancer 2016 www.cancer.ca

5 Gaudette ,LA, Gao ,RN, Wysocki ,François, Marek. Le point sur la mortalité par cancer du sein, 1995. Rapports sur la santé, no 82-003, 1997 au catalogue; 9(1):31-4.

6 Jemal, A, Siegel, R, Ward, E et al. Cancer Statistics 2007. CA Cancer J Clin 2007; 57 :43

7 Olivotto IA, Mates D, Kan L, Fung J, Samant R, Burhenne LJ. Prognosis, treatment, and recurrence of breast cancer for women attending or not attending the Screening Mammography Program of British Columbia. Breast Cancer Res Treat. 1999 Mar;54(1):73-81.

8 Berry ,D, Cronin, K, Plevritis ,S et al. Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. NEJM 2005;353,1784-1792.

9 Statistiques Canadiennes sur le cancer 2016 www.cancer.ca

10 Division de la surveillance et de l’évaluation des risques. CPCMC. Santé Canada : surveillance du cancer en direct;
http://dsol-smed.phac-aspc.gc.ca/dsol-smed/index.html

11 Statistiques Canadiennes sur le cancer 2016 www.cancer.ca

12 Statistiques Canadiennes sur le cancer 2016 www.cancer.ca

13 Statistiques Canadiennes sur le cancer 2016 www.cancer.ca

14 Familial breast cancer : collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. Lancet 2001 : 358 :1389

15 John, EM, Kelsey, JL. Radiation and other environmental exposures and breast cancer. Epidemiol rev 1993; 15 :157

16 Degnim, AC, Visscher, DW, Berman, HK, et al, Stratification of breast cancer risk in women with aypia : a Mayo cohort study. J Clin Oncol 2007; 25 :2671

17 Colditz, GA, Rosner, B. Cumulative risk of breast cancer to age 70 years according to risk factor status : data from the Nurses’Health Study. Am J Epidemiol 2000 ; 152 : 950

18 Clemons, M, Goss, P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344 :276

19 Breast cancer and breastfeeding : collaborative reanalysis of indicudual data from 47 epidemiological studies in 30 countries , including 50 302 women with breast cancer and 96 973 women without the disease. Lancet 2002; 360 :187

20 Chlebowski. RT, Hendrix, SL, Langer, RD, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women : The Women’s Health Initiative Randomized Trial.
JAMA 2003; 289 :3243

21 Titus-Ernstoff, L Hatch, EE, Hoover, RN, Palmer, J. Long-term cancer risk in women given diethylstilbestrol ( DES) during pregnancy. Br J Cancer 2001; 84 :126

22 Clemons, M, Goss, P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344 :276

23 Mertens, AJ, Sweeney, C, Shahar, E et al. Physical activity and breast cancer incidence in middle-aged women : a prospective cohort study. Breast Cancer Res Treat 2006 : 97 :209

24 Hankinson, SE, Willett, WC, Manson, JE et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in post menopausal women. J Natl Cancer Inst 1995; 87 :1297

25 Reeves GK, Pirie K and Beral V et al. (2007) Cancer incidence and mortality inrelation to body mass index in the million women study: cohort study BMJ 335 : 1134

26 Cheraghi Z, Poorolajal J and Hashem T et al (2012) Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis PloS One 7 e51446

27 Lauby-Secretant, B et al ; Body Fatness and Cancer -Viewpoint of the IARC Working Group ; N Engl J Med. 2016; 375:794-798

28 Anderson, GL, Limacher, M, Assa, AR, et al. Effects of conjugated equineestrogen in postmenopausal women with hysterectomy : the Women’s Health Initiative randomized controlled trial. JAMA 2004 : 291 :1701

29 Brisson J, Major D, Pelletier E. Évaluation de l’exhaustivité du Fichier des tumeurs du Québec, Institut national de la santé publique du Québec, 2003.

30 Kelsey ,JL, Gammon ,MD, John, EM. Reproductive factors and breast cancer.Epidemiol Rev 1993;15:36 47.

31 Aune D, Chan DS and Vieira AR et al (2012) Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies Breast Cancer Res Treat 134 479–493

32 Wu AH, Yu MC and Tseng CC et al (2008) Epidemiology of soy exposures and breast cancer risk Br J Cancer 98 9–14

33 Chen M, Rao Y and Zheng Y et al (2014) Association between soy isoflavone intake and breast cancer risk for pre- and post- menopausal women: a meta-analysis of epidemiological studies PloS One 9 e89288

34 Nechuta SJ, Caan BJ and Chen WY et al (2012) Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women Am J Clin Nutr 96 123–132

35 DongJY,ZhangLandHeK(2011)Dairy consumption and risk of breast cancer:a meta-analysis of prospective cohorts tudies Breast Cancer Res Treat 127 23–31

36 KroenkeCH,KwanMLandSweeneyCetal(2013)High-andlow-fat dairy intake,recurrence,andmortality after breast cancer diagnosis J Natl Cancer Inst 105 616–623

37 Marchbanks, PA, McDonald, JA, Wilson, HG et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346 :2025

38 Biesecker, BB, Ishibe, N, Hadley, DW et al. Psychosocial factors predicting BRCA1/BRCA 2 testing decisions in members of hereditary breast and ovarian cancer families. Am J Med Genet 2000; 93 :257

39 The Medical Letter on Drugs and Therapeutics. BRCA Screening. Vol 49 ( no 1274); 2007; pp 93-94

40 Canadian Task Force on Preventive Health Care, « Recommendations on screening for breast cancer in average-risk women aged 40-74 years », Canadian Medical Association Journal (CMAJ), 2011, vol. 183, no 17, p. 1991- 2001. 
http://canadiantaskforce.ca/guidelines/published-guidelines/breast-cancer/

41 Groupe canadien sur les soins de santé préventifs
http://canadiantaskforce.ca/cancer-du-sein-recommandations-du-depistage-par-mammographie-pour-cliniciens/?lang=fr

42 Welch, G et al; Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness; N Engl J Med 2016;375:1438-47

43 Groupe d’étude canadien sur les soins de santé préventifs 2011. Recommandations of screening for breast cancer in average-age women aged 40-74 years. Canadian medical association journal CMAJ. 2011; vol 183, no 17, pp 1991-2001
www.phac-aspc.gc.ca

44 Ministère de la santé et des services sociaux MSSS. Recommandations du groupe canadiens sur les soins de santé préventifs et impact sur le Programme québécois de dépistage du cancer du sein PQDCS. Document d'information 2011.

45 Bobo, JK, Lee, NC, Thames, SF. Findings from 752 081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 2000; 92 :971

46 Miglioretti, DL, Rutter, CM, Geller, BM, Cutter, G. Effect of Breast augmentation on the Accuracy of Mammography and Cancer Characteristics. JAMA 2004; 291 :442

47 Humphrey, LL, Helfand, M, Chan, BK, Woolf, SH. Breast cancer screening : a summary of the evidence for the U .S . Preventive Services Task Force. Ann Intern Med 2002; 137 :347

48 Weaver, DL, Rosenberg, RD, Barlow, WE, et al. Pathologic findings from the Breast Cancer Suveillance Consortium : population-based outcomes in women undergoing biopsy after screening mammography. Cancer 2006; 106 :732

49 Brown, ML, Houn, F, Sickles, EA, et al. Screening mammography in community practice : positive predictive value of abnormal findings and yield of follow-up procedures. AJR Am J Roentgenol 1995 : 165 :1373

50 Barton, MB, Morley, DS, Moore, S et al . Decreasing women’s anxieties after abnormal mammograms : a controlled trial. J Natl Caner Inst 2004; 96 :529

51 Richards, MA et al. The influence on survival of delay in presentation and treatment of symptomatic breast cancer. Br J Cancer 1999 ; 79 :858-864

52 Richards, MA et al. Influence of delay on survival in patients with breast cancer : a systematic review. Lancet 1999. 353 :858-926

53 Richard J. Bleicher, MD1; Karen Ruth, MS2; Elin R. Sigurdson, MD, PhD1; et al ; Time to Surgery and Breast Cancer Survival in the United States; JAMA Oncol. 2016;2(3):330-339.

54 Del Turco MR, Ponti A, Bick U, et al. Quality indicators in breast cancer care. Eur J Cancer. 2010; 46(13):2344-2356. 

55 Bleicher RJ, Ruth K, Sigurdson ER, et al. Preoperative delays in the US Medicare population with breast cancer. J Clin Oncol. 2012;30(36):4485- 4492. 

56 Bilimoria KY, Ko CY, Tomlinson JS, et al. Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg. 2011;253 (4):779-785. 

57 Shin DW, Cho J, Kim SY, et al. Delay to curative surgery greater than 12 weeks is associated with increased mortality in patients with colorectal and breast cancer but not lung or thyroid cancer. Ann Surg Oncol. 2013;20(8):2468-2476.

58 McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol. 2012;30(36):4493-4500. 

59 Sainsbury R, Johnston C, Haward B. Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis. Lancet. 1999;353(9159):1132-1135. 

60 Brazda A, Estroff J, Euhus D, et al. Delays in time to treatment and survival impact in breast cancer. Ann Surg Oncol. 2010;17(suppl 3):291-296.

61 NICE ; Cancer pathways UK  
- Suspected cancer recognition and referral : site or type of cancer.
- Suspected cancer recognition and referral : symptoms and findings.
- Suspected cancer recognition and referral : primary care investigation findings
https://pathways.nice.org.uk/pathways/suspected-cancer-recognition-and-referral

62 Department of Health- United Kingdom; Cancer waiting time- 2008-2011
www.dh.gov.uk

63 NICE- National Institute for Clinical Excellence- UK- Suspected cancer: recognition and referral guidance NG 12;  2015  www.nice.org.uk 
www.nice.org.uk/guidance/ng12

64 MSSS- Ministère de la santé et des services sociaux- Direction québécoise de cancérologie/Professionnels/Détection du cancer par le médecin de famille
http://www.msss.gouv.qc.ca/professionnels/cancer/detection-du-cancer-par-le-medecin-de-famille

65 Groupe d’étude canadien sur les soins de santé préventifs.
www.phac-aspc.gc.ca

66 U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. - www.ahrq.gov

67 United States Preventive Services Task Force. Guide to Clinical Preventive Services - Page générale : www.ahrq.gov

68 Programme Québécois de dépistage du Cancer du sein - www.msss.gouv.qc.ca/sujets/santepub/pqdcs/index.php?accueil

69 Programme Québécois de Dépistage du Cancer du Sein- PQDCS; Document de première ligne - www.msss.gouv.qc.ca/sujets/santepub/pqdcs/index.php?accueil

70 Programme Québécois de dépistage du Cancer du sein - www.msss.gouv.qc.ca/sujets/santepub/pqdcs/index.php?accueil

71 Fisher, B. Tamoxifen in treatment of intraductal breast cancer : National surgical adjuvant breast and bowel project B-24 randomized controlled trial. Lancet 1999; 353 :1993

72 Gotzsche, PC, Nielsen, M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.:CD001877

73 Garfinkel, L, Boring ,CC, Heath ,CW. Jr. Changing trends. An overview of breast cancer incidence and mortality. Cancer. Jul 1 1994;74 (1 Suppl):222-227.

74 Berry ,D, Cronin, K, Plevritis ,S et al. Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. NEJM 2005;353,1784-1792.

75 Sheuer, L, Kauff, N, Robson, M et al. Outcome of Preventive Surgery and Screening for Breast And Ovarian Cancer in BRCA Mutation Carriers. J Clin Oncol 2002; 20 :1260

76 National Comprehensive Cancer Network ( NCCN) Guidelines. Alliance de 21 centres oncologiques américains : www.nccn.com
Page spécifique au cancer du sein et son dépistage : www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf

77 Sheuer, L, Kauff, N, Robson, M et al. Outcome of Preventive Surgery and Screening for Breast And Ovarian Cancer in BRCA Mutation Carriers. J Clin Oncol 2002; 20 :1260

78 National Comprehensive Cancer Network ( NCCN) Guidelines. Alliance de 21 centres oncologiques américains : www.nccn.com
Page spécifique au cancer du sein et son dépistage : http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf

79 Lehman, CD, Blume, JD, Weatherall, P et al. Screening women at high risk ofr breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103 : 1898

80 Saslow, D, Boetes, C, Burke, W et al. American Cancer Society guidelines for breast cacner screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57 :75

81 US Preventive Services Task Force : Preventive medication : Breast Cancer - http://www.ahrq.gov/

82 US Preventive Task Force :http://www.ahrq.gov

83 Finch A et al; Salpingo-oophorectomy and the risk of ovarian fallopian tube, and peritoneal cancers in women with a BRCA 1 or BRCa 2 mutation. JAMA 2006; 296 :185

84 Smith, RL, Pruthi, S, Fitzpatrick, LA. Evaluation and management of breast pain. Mayo Clin Proc 2004; 79 :353

85 Venet, L, Strax, P, Venet, W, Shapiro, S. Adequacies and inadequacies of breast examinations by physicians in mass screening. Cancer 1971; 28 :1546

86 Rimsen, A, Stenkvist, B, Johanson, H, Lindgren, A. The diagnostic accuracy of palpation and fine needle biopsy and an evaluation of their combined use in the diagnosis of breast lesions : report of a prospective study in 1244 women with symptoms. Ann Surg 1975; 182 :1

87 Van Dam, PA, Van Goethem, ML, Kersschot, E et al. Palpable solid breast masses : Retrospective single and multimodality evaluations of 201 lesions. Radiology 1988; 166 :435

88 Kleer, CG, van Golen, KL, Merajver, SD. Molecular biology of breast cancer metastasis - inflammatory breast cancer : clinical syndrome and molecular determinants. Breast Cancer Res 2000; 2 : 423

89 Smart, CR, Hartmann, WH, Beahrs, OH, Garfinkel, L. Insights into breast cancer screening of younger women. Evidence from the 14-year follow-up of the Breast Cancer Dectection Demonstration Project. Cancer 1993; 72 :1449

90 Barlow, WE, Lehman, CD, Zheng, Y et al. Performance of diagnostic mammographiy for women with signs or symptoms of breast cancer. J Natl Cancer Inst 2002; 94 :1151

91 Moller, H  et al ; Use of the English urgent referral pathway for suspected cancer and mortality in patients with cancer : cohort study. BMJ 2015. 2015 ; 351:h5102

92 Stomper, PC. Breast imaging. In : Atlas of Breast Cancer, Hayes, DF(Ed). Mosby, Philadelphia 2000. P.54.

93 Smith, RL, Pruthi, S, Fitzpatrick, LA. Evaluation and management of breast pain. Mayo Clin Proc 2004; 79 :353

94 Barlow, WE, Lehman, CD, Zheng, Y et al. Performance of diagnostic mammographiy for women with signs or symptoms of breast cancer. J Natl Cancer Inst 2002; 94 :1151

95 Donegan, WL; Evaluation of a palpable breast mass. N Engl J Med 1992; 327 :937

96 NCCN- National Comprenhensive Cancer Network : Clinical practice guidelines in oncology;
Site américain d’oncologie qui offre des recommandations détaillées sur le dépistage et l’investigation du cancer du sein  www.nccn.org/professionals/physician_gls/PDF/breast-screening.pdf

97 Department of Health- United Kingdom; Guidance NG 12; 2015
https://www.gov.uk/government/organisations/department-of-health
www.nice.org.uk/guidance.ng12

98 Bluemke, DA, Gatsonis, CA, Chen, MH et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292 :2735

99 Hulka, CA, Smith, BL, Sgroi, DC, et al. Benign and malignant breast lesions : differenciation with echo-planar MR imaging. Radiology 1995 : 197 :33

100 Sickles, EA, Filly, RA, Callen, PW. Benign breast lesions :Ultrasound detection and diagnosis. Radiology 1984; 151 :467

101 Moy, L, Slanetz, PJ, Moore, R et al. Specificity of mammography and US un the evaluation of a palpable abnormality : retrospective rewiew. Radiology 2002; 225 :176

102 Rahbar, G, Sie, AC, Hansen, GC et al. Benign versus malignant solid breast masses : US differentiation.Radiology 1999 : 213 :889

103 Ciatto, S, Cariaggi, P, Bulgaresi, P. The value of routine cytologic examination of breast cyst fluids. Acta Cytol 1987; 31 :301

104 Giard, RW, Hermans, J. The value of aspiration cytologic examination of the breast . Cancer 1992; 69 :2104

105 Pisano, ED, Fajardo, LL, Caudry, DJ et al. Fine-needle aspiration biopsy of non palpable breast lesions in a multicenter clinical trial : results from the radiologic diagnostic oncology group V. Radiology 2001; 219 :785

106 Antley, CM, Mooney, EE, Layfield, LJ. A comparison of accuracy rates between open biopsy, cutting-needle biopsy , and fine-needle aspiration biopsy of the breast; a 3 year experience. Breast Journal 1998; 4 : 3

107 Ballo, MS, Sneige, N. Can core needle biopsy replace fine-needle aspiration cytology in the diagnosis of palpable breast carcinoma. A comparative study of 124 women. Cancer 1996; 78 : 773

108 Layfield, LJ, Glasgow, BJ, Cramer, H. Fine-needle aspiration in the management of breast masses. Pathol Annu 1989; 24 :23

109 Ikeda, DM, Helvie, MA, Franks, TS et al. Paget disease of the nipple : radiologic-pathologic correlation. Radiology 1993; 189 :89

110 Moller, H  et al ; Use of the English urgent referral pathway for suspected cancer and mortality in patients with cancer : cohort study. BMJ 2015. 2015 ; 351:h5102

111 Caplan, L et al ; Delay in breast cancer : implications for stage at diagnosis and survival. 

112 Frontiers in Public Health ; 2015 ; vol 2 ; article 87

113 Richards, et al ; Influence of delay on survival in patients with breast cancer : a systematic review. Lancet 1999 ; 353 : 1119-26

114 Bleicher R, et al ; Time to surgery and breast cancer survival in the United States. Jama oncology 2016 ; Vol 2, No 3, pp 331-339

115 NICE ; Cancer pathways UK  
- Suspected cancer recognition and referral : site or type of cancer.
- Suspected cancer recognition and referral : symptoms and findings.
- Suspected cancer recognition and referral : primary care investigation findings
https://pathways.nice.org.uk/pathways/suspected-cancer-recognition-and-referral

116 Site anglais NICE : National Institute for Health and Clinical Excellence -pages spécifiques au cancer du sein - www.nice.org.uk

117 Mayo, JR. Magnetic resonance imaging of the chest. Where we stand. Radiol Clin North Am 1994; 32 :795

118 Lyman, GH, Giuliano, AE, Somerfield, MR, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node biopsy in Early-Stage Breast Cancer. J Clin Oncol 2005 : 237 : 390

119 Ferlicot, S, Vincent-Salomon, A, Medioni,J, et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 2004; 40 :336

120 Li, CI, Moe, RE, Daling, JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 ans; Arch Intern Med 2003; 163 :2149

121 Sullivan, T, Raad, Ra, Goldberg, S et al. Tubular carcinoma of the breast : a retrospective analysis and review of the literature. Breast Cancer Res Treat 2005; 93 :199

122 AJCC ( American Joint Committee on Cancer) Cancer Staging Manual Greene,  FL, Page, DL, Fleming, ID, Fritz, A, Balch, CM, Haller, DG, Morrow, A eds. AJCC Cancer Staging Manual. 6th edition. Berlin :Springer Verlag 2002 :223-240

123 Site français de cancérologie du Professeur Jean-François HERON; Faculté de médecine de CAEN; Excellents textes résumés sur la classification du cancer du sein. www.oncoprof.net/Generale2000/g06_Classification/g06_cl14.html

124 GEOQ- Site québécois d’oncologie destiné aux médecins, portant sur le traitement des principaux cancers et leur stadification détaillée - mot de passe nécessaire;  Site accessible à tous les médecins : www.geoq.com

125 AJCC ( American Joint Committee on Cancer) Cancer Staging Manual, 6th ed, Greene, FL, Page, DL, Fleming, ID, et al ( Eds). Springer-Verlag, New York, 2002, pp223-240

126 Bleicher R, et al ; Time to surgery and breast cancer survival in the United States. Jama oncology 2016 ; Vol 2, No 3, pp 331-339

127 Richards, et al ; Influence of delay on survival in patients with breast cancer : a systematic review. Lancet 1999 ; 353 : 1119-26

128 NICE ; Cancer pathways UK  
- Suspected cancer recognition and referral : site or type of cancer.
- Suspected cancer recognition and referral : symptoms and findings.
- Suspected cancer recognition and referral : primary care investigation findings
https://pathways.nice.org.uk/pathways/suspected-cancer-recognition-and-referral

129 Garfinkel, L, Boring ,CC, Heath ,CW. Jr. Changing trends. An overview of breast cancer incidence and mortality. Cancer. Jul 1 1994;74 (1 Suppl):222-227.

130 Harris, L, Fritsche H, Mennel, R et al. American Society of Clinical Oncology 2007. Update of recommandations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25 : 5287

131 Statistiques canadiennes sur le cancer : www.cancer.ca

132 Hébert-Croteau N, Brisson J, Latreille J, Rivard M, Abdelaziz N, Martin G. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with nodenegative breast cancer. J Clin Oncol. 2004 Sep 15;22 (18) : 3685-93.

133 Berry ,D, Cronin ,K, Plevritis ,S et al. Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. NEJM 2005;353,1784-1792.

134 Harris JR, Lippman ME, Veronsei U, Willett WC. Breast Cancer. N Engl J Med 1992; 327 (3 parties) : 319-28, 390-8, 473-80.

135 Heikki Joensuu; Tiina Lehtimäki; Kaija Holli; Liisa Elomaa; Taina Turpeenniemi- Hujanen; Vesa Kataja; Ahti Anttila; Mikael Lundin; Jorma Isola; Johan Lundin, Risk for Distant Recurrence of Breast Cancer Detected by Mammography Screening or
Other Methods. JAMA. 2004;292:1064-1073.

136 Ragaz J, Olivotto I, Spinelli J et al. Locoregional Radiation Therapy in Patients with High-Risk Breast Cancer Receiving Adjuvant Chemotherapy:20-Year Results of British Columbia Randomized Trial.  JNCI 2005, Vol.97, No.2, 116-126.

137 Statistiques canadiennes sur le cancer 2016 : www.cancer.ca

138 Kollmorgen, DR, Varanasi, JS, Edge, SB, Carson, WE. Paget’s disease of the breast : a 33 year experience. J Am Coll surg 1998; 187 :171

139 N. Harris et al ; Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Lyndsay Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline 2016 ; J Clin Oncol 34. 

140 Harris, L, Fritsche, H, Mennel, R et al. American Society of Clinical Oncology 2007- Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25 :5287

141 GEOQ- Site québécois d’oncologie destiné aux médecins, portant sur le traitement des principaux cancers et leur stadification détaillée - mot de passe nécessaire, mais site accessible à tous les médecins : www.geoq.com

142 NCCN –Site Internet américain d’oncologie National Comprenhensive Cancer Network;
Traitements détaillés du cancer du sein et de son suivi : www.nccn.org/professionals/physician_gls/default.asp

143 Site anglais NICE : National Institute for Health and Clinical Excellence –Recommandations spécifiques (Guideline) au cancer du sein;
www.nice.org.uk

144 SIGN (Scottish InterCollegiate Guidelines Network); Management of breast cancer in women; A National Clinical Guideline.
www.sign.ac.uk

145 Kinne, DW, Petrek, JA, Osborne, MP, et al Breast carcinoma in situ. Arch surg 1989; 124 :33

146 Solin, LJ, Fourquet, A, Vicini, FA, et al. Salvage treatment for local recurrence after breast-conservating surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast. Cancer 2001; 91 : 1090

147 Hughes, KS, Schnaper, LA, Berry, D et al. Lumpectomy plus tamoxifen with or without radiotherapy in women 70 years of age or older with early breast cancer. J Engl J Med 2004; 351 :971

148 Société Canadienne du Cancer - Informations générales sur les cancers : www.cancer.ca

149 Santé Canada : www.hc-sc.gc.ca

150 Association Québécoise du Lymphœdeme : www.infolympho.ca

151 Fondation du Cancer du sein du Québec : www.rubanrose.org

152 Réseau Canadien sur le cancer du sein : www.cbcn.ca

153 Groupe virage de l’hôpital Notre Dame, Montréal : www.viragecancer.org

154 Site Canadien Fortes Ensemble : qui offre un répertoire exhaustif de liens internet vers des sites canadiens reconnus, selon la thématique
     Site Canadien Willow : www.willow.org
     The Canadian Breast Cancer Network : www.cbcn.ca
     Le site canadien Rethink Breast Cancer : www.rethinkbreastcancer.com
     Breast Cancer Now What ?: www.breastcancernowwhat.ca
     Site anglais CancerBack up : www.cancerbackup.org.uk
     Site australien The Breast Cancer Network Australia : www.breastcancer.org
     Oncolink , site américain : www.oncolink.com
 
155 Oncolor : Site français de la région de Lorraine, présentant des référentiels médicaux d’investigation et de traitements, mis à jour, portant sur les principaux cancers : www.oncologik.fr
Page spécifiques au cancer du sein : www.oncologik.fr

156 Oncoprof - Site français de cancérologie du Professeur Jean-François HERON; Faculté de médecine de CAEN; Excellents textes résumés sur l’oncologie générale. www.oncoprof.net

157 Société Canadienne du Cancer - Informations spécifiques sur le cancer : http://www.cancer.ca/Quebec/About%20cancer/Types%20of%20cancer/What%20is%20breast%20cancer.aspx?sc_lang=fr-CA&r=1

158 Oncolor : Site français de la région de Lorraine, présentant des référentiels médicaux d’investigation et de traitements, mis à jour, portant sur les principaux cancers : référentiel sur le cancer du sein
www.oncologik.fr

159 NCI : National Institute of cancer – USA. Site américain www.cancer.gov/cancertopics

160 Cancer Net- Société américaine d’oncologie clinique - Informations pour les patients
www.plwc.org/portal/site/PLWC

161 Le site américain, en langue anglaise,Uptodate, qui garde à jour des informations basées sur les évidences scientifiques des traitements actuels. Il y un texte spécifique pour chaque cancer  www.patients.uptodate.com

162 Pierce JP, Stefanick ML and Flatt SW et al (2007) Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity J Clin Oncol 25 2345–2351

163 SmithSL,Singh CarlsonS and DownieL(2011)Survivors of breast cancer:patient perspectives on survivorship care planning J Cancer Surviv 5 337–344 

164 Hewitt MG and Ganz PA (2007) Implementing Cancer Survivorship Care Planning Washington DC: The National Academies Press

165 Holmberg L, Anderson, H. HABITS (hormonal replacement therapy after breast cancer- Is it safe ?); A randomised comparison: trial stopped. Lancet 2004 feb; 7; 363 (9407) : 453-455

166 SOGC - Société Canadienne des gynécologues et obstétriciens du Canada. Recours à l’hormonothérapie substitutive après un traitement contre le cancer du sein
http://sogc.org

167 SOGC - Société Canadienne des gynécologues et obstétriciens du Canada.
The detection and management of vaginal atrophy :
http://sogc.org

168 SOGC - Consensus Canadien sur le traitement de la ménopause
http://sogc.org

169 Melisko ME, Goldman ME, Hwang J, et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2016 Nov 10

170 US Food and Drug Administration. FDA approves Intrarosa for postmenopausal women experiencing pain during sex.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm529641.htm

171 Barber, RJ, et al ; IMS recommandations on women’s midlife health and menopause hormone therapy ; Climacteric. 2016 Apr;19 (2):109-50. 

172 Loprinzi CL, Kugler JW, Sloan J, Mailliard A, LaVasseur B, Barton D, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized trial. Lancet 2000;356:2059-63.

173 Chen Z; Maricic M; Bassford TL; Pettinger M; Ritenbaugh C; Lopez AM; Barad DH; Gass M; Leboff MS; Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 2005 Mar 14;165 (5) : 552-8.
 
174 SOGC; Conférence canadienne de consensus sur l’ostéoporose, mise à jour 2006. Directives cliniques de la; No 172; février 2006;
www.sogc.org

175 Pouillès JM, Ribot C. Cancer du sein et risque d’ostéoporose. Lettre Rhumatologique 2005; 310 : 26-32

176 Association Québécoise du Lymphœdeme; www.infolympho.ca

177 Piccart, MJ et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer; NEJM;
2005; 353; 1659-1672

178 Sisler, J et al ; Suivi après le traitement du cancer du sein Guide pratique des soins aux survivantes à l’intention des médecins de famille ;  Le Médecin de famille canadien | VOL 62: OCTOBER OCTOBRE 2016 

179 Comité consultatif des Statistiques canadiennes sur le cancer de la Société canadienne du cancer.Canadian cancer statistics, 2015. Special topic: predictions of the future burden of cancer in Canada. Toronto, ON : Société canadienne du cancer; 2015.

180 Worster, A, Wood, M L, McWhinney, I, Bass, M, J. Who provides follow-up care for patients with early breast cancer ? Canadian Family Physician; 1995; 41 : 1314-1320

181 De Bock GH, Bonnema J, van Der Hage J, Kievit J, van de Velde CJH. Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta- analysis and systematic review. J Clin Oncol 2004;22(19):4010-8. 

182 Luctkar-Flude M, Aiken A, McColl MA, Tranmer J. A comprehensive frame- work and key guideline recommendations for the provision of evidence-based breast cancer survivorship care within the primary care setting. Fam Pract 2014;32(2):129-40. 

183 Willis A, Hoffler E, Villalobos A, Pratt-Chapman M. National Cancer Survivorship Resource Center toolkit. Provider tools. Implementing clinical practice guide-lines for cancer survivorship care. Washington, DC: George Washington Cancer Institute, American Cancer Society; 2016.

184 Groupe d’étude canadien sur les soins de santé préventifs
www.phac-aspc.gc.ca

185 Khatcheressian, JL, Wolff, AC, Smith, TJ et al. American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-up and Management Guidelines in the Adjuvant Setting. J Clin Oncol 2006; 24 : 5091-5097

186 Site anglais NICE : National Institute for Health and Clinical Excellence -page spécifique au cancer du sein : www.nice.org.uk

187 Siller, J, Chaput, G, Sussman, J, Ozokwelu, E. Suivi après le traitement du cancer du sein ; Guide pratique des soins aux survivantes à l’intention des médecins de famille. Médecine de famille Canadien oct 2016, vol 62

188 Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F et coll. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31(7):961-5. Publ. en ligne du 5 nov. 2012 

189 Shockney LD. Management of long-term side effects. Dans: Shockney LD, rédacteur. Breast cancer survivorship care: a resource for nurses. Sudbury, MA: Jones and Bartlett Publishers; 2011. p. 36-58

190 Frost MH, Suman VJ, Rummans TA, Dose AM, Taylor M, Novotny P et coll. Physical, psychological and social well-being of women with breast cancer: the influence of disease phase. Psychooncology 2000;9(3):221-31

191 Groupe d’étude canadien sur les soins de santé préventifs
www.phac-aspc.gc.ca

192 Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R et coll. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev 2005;(1):CD001768 

193 Hoff, PM, Valero, V, Buzdar, AU, et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 2000; 88 : 2054

194 SOGC /GOC Joint Clinical Practice Guidelines. Progesterone-Only and Non-Hormonal Contraception in the Breast Cancer Survivor : Joint Review and Committee Opinion of the Society of Obstetricians and Gynaecologists of Canada and  the Society of Gynecology Oncologists of Canada. Juillet 2006, No.179.

195 Kaufmann, M, Hortobagyi, GN, Goldhirsch, A et al. Recommandations from an international expert panel on the use of neoadjuvant ( primary) systemic treatment for operable breast cancer : an update. J Clin Oncol 2006; 24 : 1940

196 Miniguide de Palli-Science ; www.maisonvictor-gadbois.com.
Produit par la maison Victor Gadbois; Saint Mathieu de Beloeil; ce guide de thérapeutique en soins palliatifs est mis à jour annuellement

197 Hoskin Peter, Makin Wendy. Oncology for Palliative Medicine; Oxford Press 2003; Chapitre 9 : Breast Cancer; pp 109

198 Hoskin Peter, Makin Wendy. Oncology for Palliative Medicine; Oxford Press 2003; Chapitre 9 : Breast Cancer; pp 111